C3 degradation products (C3d) in normal pregnancy

J S JENKINS, R J POWELL

From the Department of Immunology, University Hospital, Nottingham

SUMMARY Plasma C3 degradation products (C3d) were measured in 65 normal pregnancies and compared with those of non-pregnant women. No significant difference was detected between the two groups, although a difference had been previously reported. Plasma C3d estimations give an indication of complement activation and may be used as an indicator of disease activity in patients with systemic lupus erythematosus (SLE), irrespective of pregnancy.

Systemic lupus erythematosus (SLE) predominantly affects women of child bearing age and is a classical immune complex disease in which hypocomplementaemia is a feature, but the hypocomplementaemia reflects not only complement activation but also hypoproduction. Quantification of C3d, a product of C3 activation, by the alternative or classical complement pathways, gives an indirect measurement of complement activation. The concentration of C3d can be used as an indicator of lupus activity. The role of C3d estimations in the management of pregnant women with SLE was questioned by a report, which stated that pregnancy itself could increase complement turnover, thus producing high C3d concentrations. We therefore measured the concentrations in a group of pregnant women.

Material and methods

Sixty five women at various stages of pregnancy were randomly requested to give an extra sample of blood during routine venepuncture at an antenatal clinic. Women with pregnancy complications or who were receiving drugs were not excluded. The edetic acid plasma was separated within six hours of venepuncture and stored at −186°C in a vapour phase liquid nitrogen container. A control group comprised 21 non-pregnant women and 18 men (age range 18 to 83 years).

C3d concentrations were measured using the double decker rocket immunoelectrophoresis method of Brandslund et al. Essentially, electrophoresis of 4 μl edetic acid plasma was performed overnight (2.5 V/cm) initially through a gel layer containing antihuman C3c (Dako) and then through a layer containing antihuman C3d (Dako) where the C3d rockets were formed. After drying and staining the rocket heights of test samples and standards were measured and the C3d values calculated from a standard curve. The C3d concentration of the standard (normal serum incubated at 37°C for four days) was assigned an arbitrary value of 100 units/ml.

Results

Plasma C3d concentrations in the pregnant women were mean 8.2 (SD 2.3) units/ml. These values did not differ significantly from those found in controls (8.6 (2-3) units/ml) when the data were analysed using Student's t test (t = 0.06, 0.3 < p < 0.4). The C3d concentration exceeded normal limits as defined by

Accepted for publication 28 May 1987

Fig 1 C3d concentrations in a) 39 normal controls and b) 65 pregnant women.
C3 degradation products (C3d) in normal pregnancy

the mean (SD) range in only one (1.5%) sample from a pregnant woman (fig 1). Fig 2 shows C3d concentrations in relation to the duration of pregnancy.

![Graph showing C3d concentrations in relation to duration of pregnancy.](image)

**Fig 2** Plasma C3d concentration related to duration of pregnancy.

**Discussion**

Detectable amounts of C3d were present in all of the normal controls as well as in the pregnant women. This is not surprising because a “priming” C3 convertase is slowly assembled, continuously producing small amounts of C3 breakdown products. Our results indicate that the plasma C3d concentration is not significantly increased in pregnancy. Our findings do not agree with those of Teisner et al, who reported significant increases of C3d in the second and third trimesters when compared with non-pregnant women, those in the puerperium, or those in the first trimester of pregnancy. Furthermore, our study shows similar C3d concentrations in all three trimesters. We conclude that the value of C3d measurements is unaffected by uncomplicated pregnancy and can be used to monitor complement activation in systemic lupus erythematosus irrespective of pregnancy.

We thank Ms N Richards for her technical assistance and Mrs E Hall for her secretarial help.

**References**


Requests for reprints to: Dr R J Powell, Consultant Immunologist, University Hospital, Queen’s Medical Centre, Nottingham NG7 2UH, England.
C3 degradation products (C3d) in normal pregnancy.

J S Jenkins and R J Powell

doi: 10.1136/jcp.40.11.1362

Updated information and services can be found at:
http://jcp.bmj.com/content/40/11/1362

**Email alerting service**

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/